VA111913 for Dysmenorrhea
VA111913 is a novel small molecule drug, discovered by Vantia, and in clinical development for the treatment of dysmenorrhoea. Dysmenorrhoea is a condition characterised by abnormal contractions of the uterus and constriction of uterine blood vessels during menstruation which causes abdominal cramping and pain. VA111913 acts by specifically blocking vasopressin V1a receptors in smooth muscle in the uterus wall and blood vessels. It is the stimulation of the V1a receptors by elevated vasopressin levels that results in the symptoms of dysmenorrhoea.
In pre-clinical trials, VA111913 has demonstrated inhibition of contraction of human uterus stimulated by vasopressin thereby offering the potential to be a first-in-class drug that directly targets the cause of the pain associated with dysmenorrhoea.
In its first clinical trials, VA111913 was safe and well tolerated. Exploratory Phase II clinical data showed promising evidence of reduced pain levels in patients with dysmenorrhoea who received VA111913. Statistically significant differences between VA111913 treatment and placebo were seen for a number of efficacy endpoints, and the study identified a target population that benefited from a substantial reduction in pain when treated with VA111913.
Dysmenorrhoea has been estimated to affect between 50% and 90% of women of reproductive age. There are no available therapies targeted to the underlying cause of the pain i.e. muscle cramping and as such VA111913 would be a first-in-class approach for this often debilitating condition. Treatments that are commonly administered include over-the-counter painkillers e.g., NSAIDs, however a significant number of women continue to suffer substantial pain and as a result seek medical attention. The treatment options for these women are limited and commonly include prescription strength NSAIDs or “off-label” use of oral contraceptives. As a result of limited efficacy and/or undesirable side effects a large proportion of dysmenorrhoea sufferers remain poorly treated and Vantia believes represent a significant unmet clinical need. Market research suggests that 50% of women who present to a medical practitioner could benefit from treatment with VA111913 and predict annual global sales in excess of $1 billion.